• Galmed reported successful first-in-human proof-of-concept results for Colospan’s intraoperative colon tissue assessment platform.
• Results have been presented in the announcement, with the study meeting its feasibility objective during elective colorectal cancer surgery.
• The trial produced usable tissue-quality measurements in every patient, supporting further development toward an intraoperative device for surgical decision-making.
• The program broadens Colospan beyond its CG-100 bypass device, positioning a second platform for future trials and regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608190700PR_NEWS_USPR_____IO29419) on August 19, 2026, and is solely responsible for the information contained therein.